Active Ingredient(s):Copanlisib FDA Approved: * September 14, 2017 Pharm Company: *BAYER HEALTHCARE PHARMS Category:Cancer
Copanlisib (trade name Aliqopa /ælkop/ AL-ih-KOH-pah; codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells.
Efficacy resulting in the approval of copanlisib was based on the subgroup of 104 patients with follicular lym...
* May have multiple approval dates, manufacturers, or labelers.
Aliqopa 15 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution